ubiquinone and Fatigue

ubiquinone has been researched along with Fatigue* in 25 studies

Reviews

4 review(s) available for ubiquinone and Fatigue

ArticleYear
The mechanism and prevention of mitochondrial injury after exercise.
    Journal of physiology and biochemistry, 2021, Volume: 77, Issue:2

    With the development of society, physical activity has come to be an effective means by which people pursue good health to improve the quality of life. However, with the increase of intensity and the passage of time, exercise injury has become a hazard that can no longer be ignored. It is imperative to find effective ways to inhibit or reduce the negative effects of exercise. Mitochondria are important organelles involved in exercise and play an important role in exercise injury and prevention. Studies have found that exercise preconditioning and increased mitochondrial nutrition can effectively decrease mitochondrial damage after exercise. Against this background, some of the newest developments in this important field are reviewed here. The results discussed indicate that exercise preconditioning and supplement mitochondrial nutrition need to be increased to prevent exercise-related injuries.

    Topics: Apoptosis; Athletic Injuries; Calcium; Dietary Supplements; DNA Damage; Exercise; Fatigue; Free Radicals; Humans; Lipid Peroxidation; Mitochondria; Nitric Oxide; Phenylethyl Alcohol; Resveratrol; Thioctic Acid; Ubiquinone

2021
Effect of coenzyme Q10 supplementation on fatigue: A systematic review of interventional studies.
    Complementary therapies in medicine, 2019, Volume: 43

    A number of studies have examined the beneficial effects of Coenzyme Q10 (CoQ10) on fatigue in different population, but the findings have been inconclusive. Herein, we systematically reviewed available interventional studies to elucidate the overall effects of CoQ10 supplementation on fatigue among adolescent and adult population.. PubMed, Cochrane's library, Science direct, Scopus, Google scholar and ISI web of science databases were searched for all available literature until April 2018 for studies assessing the effects of CoQ10 supplementation on fatigue. The Cochrane bias assessment tool were used to assess the quality of studies.. A total of 16 studies out of 1316 met our inclusion criteria and included in our systematic review. Among included studies 10 of them showed significant beneficial effects (p < 0.05) of CoQ10 supplementation on fatigue status among healthy, fibromyalgia, statin-related fatigue, multiple sclerosis and end-stage heart failure subjects. CoQ10 supplementation could alleviate fatigue, but differences between studies population should be taken into account.. It seems CoQ10 has better therapeutic effects in statin-related fatigue and fibromyalgia patients compared with the other disease related fatigue. Finally, in order to draw a firm link between CoQ10 and fatigue, more clinical trials with adequate sample size and with sufficient follow-up periods are needed.

    Topics: Dietary Supplements; Fatigue; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nutrition Therapy; Ubiquinone

2019
Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of the Italian Network of mitochondrial diseases.
    Neuromuscular disorders : NMD, 2012, Volume: 22 Suppl 3

    Fatigue and exercise intolerance are common symptoms of mitochondrial diseases, but difficult to be clinically assessed. New methods to quantify these rather common complaints are strongly needed in the clinical practice. Coenzyme Q10 administration and aerobic exercise may improve exercise intolerance, but more definite studies are still pending. Herein, we have revised "how to measure" and "how to treat" these symptoms of mitochondrial patients. Subsequently, we reviewed the clinical data of the 1164 confirmed mitochondrial patients present in the Italian nation-wide database of mitochondrial disease, with special regard to exercise intolerance. We observed that more of 20% of mitochondrial patients complain of exercise intolerance. This symptom seems to be frequently associated with specific patient groups and/or genotypes. Ragged red fibers and COX-negative fibers are more often present in subjects with exercise intolerance, whereas lactate levels could not predict this symptom. Multicenter efforts are strongly needed for rare disorders such as mitochondrial diseases, and may represent the basis for more rigorous longitudinal studies.

    Topics: Exercise; Fatigue; Humans; Mitochondrial Diseases; Mutation; Ubiquinone

2012
Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy.
    Clinical & experimental metastasis, 2008, Volume: 25, Issue:2

    Metastatic cancers are associated with cellular oxidative stress, and during cancer chemotherapy excess drug-induced oxidative stress can limit therapeutic effectiveness and cause a number of side effects, including fatigue, nausea, vomiting, diarrhea and more serious adverse effects, such as cardiomyopathy, peripheral neuropathy, hepatotoxicity and pulmonary fibrosis. We review here the hypothesis that the acute and chronic adverse effects of cancer chemotherapy can be reduced by molecular replacement of membrane lipids and enzymatic cofactors, such as coenzyme Q(10). By administering nutritional supplements with replacement molecules and antioxidants, oxidative membrane damage and reductions of cofactors in normal tissues can be reversed, protecting and restoring mitochondrial and other cellular functions and reducing chemotherapy adverse effects. Recent clinical trials using cancer and non-cancer patients with chronic fatigue have shown the benefit of molecular replacement plus antioxidants in reducing the damage to mitochondrial membranes, restoring mitochondrial electron transport function, reducing fatigue and protecting cellular structures and enzymes from oxidative damage. Molecular replacement and antioxidant administration mitigates the damage to normal tissues, such as cardiac tissue, and reduces the adverse effects of cancer therapy without reduction in therapeutic results.

    Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antioxidants; Dietary Supplements; Fatigue; Humans; Lipid Peroxidation; Membrane Lipids; Mitochondria; Neoplasm Metastasis; Oxidative Stress; Ubiquinone

2008

Trials

12 trial(s) available for ubiquinone and Fatigue

ArticleYear
Beneficial Effect of Ubiquinol on Hematological and Inflammatory Signaling during Exercise.
    Nutrients, 2020, Feb-06, Volume: 12, Issue:2

    Strenuous exercise (any activity that expends six metabolic equivalents per minute or more causing sensations of fatigue and exhaustion to occur, inducing deleterious effects, affecting negatively different cells), induces muscle damage and hematological changes associated with high production of pro-inflammatory mediators related to muscle damage and sports anemia. The objective of this study was to determine whether short-term oral ubiquinol supplementation can prevent accumulation of inflammatory mediators and hematological impairment associated to strenuous exercise. For this purpose, 100 healthy and well-trained firemen were classified in two groups: Ubiquinol (experimental group), and placebo group (control). The protocol was two identical strenuous exercise tests with rest period between tests of 24 h. Blood samples were collected before supplementation (basal value) (T1), after supplementation (T2), after first physical exercise test (T3), after 24 h of rest (T4), and after second physical exercise test (T5). Hematological parameters, pro- and anti-inflammatory cytokines and growth factors were measured. Red blood cells (RBC), hematocrit, hemoglobin, VEGF, NO, EGF, IL-1ra, and IL-10 increased in the ubiquinol group while IL-1, IL-8, and MCP-1 decreased. Ubiquinol supplementation during high intensity exercise could modulate inflammatory signaling, expression of pro-inflammatory, and increasing some anti-inflammatory cytokines. During exercise, RBC, hemoglobin, hematocrit, VEGF, and EGF increased in ubiquinol group, revealing a possible pro-angiogenic effect, improving oxygen supply and exerting a possible protective effect on other physiological alterations.

    Topics: Chemokine CCL2; Cytokines; Double-Blind Method; Erythrocyte Count; Exercise; Exercise Test; Fatigue; Female; Hematocrit; Hemoglobins; Humans; Inflammation Mediators; Intercellular Signaling Peptides and Proteins; Interleukin-1; Male; Muscle, Skeletal; Oxygen Consumption; Signal Transduction; Ubiquinone

2020
Coenzyme Q10 as a treatment for fatigue and depression in multiple sclerosis patients: A double blind randomized clinical trial.
    Nutritional neuroscience, 2016, Volume: 19, Issue:3

    Multiple sclerosis (MS) is the chronic inflammatory and demyelinating disorder of central nervous system which is accompanied with disability and negative life style changes such as fatigue and depression. The aim of this study is to investigate the effect of coenzyme Q10 (CoQ10) supplementation on fatigue and depression in patients with MS.. We performed a randomized, double-blinded, placebo-controlled trial to determine the effect of CoQ10 supplement (500 mg/day) vs. placebo for 12 weeks. Fatigue symptoms were quantified by means of fatigue severity scale (FSS) and the Beck depression inventory (BDI) was used to assess depressive symptoms.. A significant decrease of FSS was observed in CoQ10 group during the intervention (P = 0.001) and significant increase of FSS change was observed within placebo group (P = 0.001). Repeated measure analysis of variance showed a significant time-by-treatment interaction for FSS (baseline 41.5 ± 15.6 vs. endpoint 45 ± 13.6; F1,45 = 55.23, P < 0.001, η(2) = 0.56) and BDI (baseline 17.8 ± 12.2 vs. endpoint 20.4 ± 11.4; F1,45 = 40.3, P < 0.001, η(2) = 0.48), indicating significant decrease of FSS and BDI in CoQ10 group compared to placebo group.. Our study suggests that CoQ10 supplementation (500 mg/day) can improve fatigue and depression in patients with multiple sclerosis.

    Topics: Adult; Antidepressive Agents; Antioxidants; Combined Modality Therapy; Depression; Dietary Supplements; Double-Blind Method; Fatigue; Female; Humans; Iran; Male; Multiple Sclerosis; Oxidative Stress; Patient Dropouts; Psychiatric Status Rating Scales; Self Report; Severity of Illness Index; Ubiquinone

2016
Efficacy and safety of an amino acid jelly containing coenzyme Q10 and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy: a multi-institutional, randomized, exploratory trial (JORTC-CAM01).
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, Volume: 24, Issue:2

    Cancer-related fatigue (CRF) is one of the most common symptoms reported by cancer patients. This randomized trial investigated the efficacy of the amino acid jelly Inner Power(®) (IP), a semi-solid, orally administrable dietary supplement containing coenzyme Q10 and L-carnitine, in controlling CRF in breast cancer patients in Japan.. Breast cancer patients with CRF undergoing chemotherapy were randomly assigned to receive IP once daily or regular care for 21 days. The primary endpoint was the change in the worst level of fatigue during the past 24 h (Brief Fatigue Inventory [BFI] item 3 score) from day 1 (baseline) to day 22. Secondary endpoints were change in global fatigue score (GFS; the average of all BFI items), anxiety and depression assessed by the Hospital Anxiety and Depression Scale (HADS), quality of life assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Breast Cancer-Specific QLQ (EORTC QLQ-BR23), and adverse events.. Fifty-nine patients were enrolled in the study, of whom 57 were included in the efficacy analysis. Median patient age was 50 years. Changes in the worst level of fatigue, GFS, and current feeling of fatigue were significantly different between the intervention and control groups, whereas the change in the average feeling of fatigue was not significantly different between groups. HADS, EORTC QLQ-C30, and EORTC QLQ-BR23 scores were not significantly different between the two groups. No severe adverse events were observed.. IP may control moderate-severe CRF in breast cancer patients.. The registration number of this study in the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR) is UMIN000008646.

    Topics: Adult; Aged; Breast Neoplasms; Carnitine; Fatigue; Female; Humans; Middle Aged; Quality of Life; Ubiquinone

2016
Ubiquinol-10 supplementation improves autonomic nervous function and cognitive function in chronic fatigue syndrome.
    BioFactors (Oxford, England), 2016, Jul-08, Volume: 42, Issue:4

    The aim of this study was to evaluate the benefit of oral ubiquinol-10 supplementation in CFS patients using an open-label study and a randomized, double-blinded, placebo-controlled (RCT) study. Twenty patients with CFS were randomly enrolled in an 8-week open-label oral ubiquinol-10 (150 mg ubiquinol-10/day) study. The patients and the attending physicians were not blinded to the supplementation. Forty-three patients with CFS were randomly assigned to receive either ubiquinol-10 (150 mg/day) or placebo every day for 12 weeks. The patients and the attending physicians were blinded to the supplementation, and a total of 31 patients (N = 17 in the ubiquinol group and 14 in the placebo group) completed the study. The beneficial effects of ubiquinol-10 were observed in the open-label study we conducted prior to the RCT. The RCT results suggest that supplementation with ubiquinol-10 for 12 weeks is effective for improving several CFS symptoms. © 2016 BioFactors, 42(4):431-440, 2016.

    Topics: Administration, Oral; Adult; Antioxidants; Autonomic Nervous System; Biomarkers; Dietary Supplements; Double-Blind Method; Fatigue; Fatigue Syndrome, Chronic; Female; Humans; Male; Treatment Outcome; Ubiquinone

2016
Coenzyme Q10 supplementation downregulates the increase of monocytes expressing toll-like receptor 4 in response to 6-day intensive training in kendo athletes.
    Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme, 2015, Volume: 40, Issue:6

    This study examined changes in toll-like receptor 4 (TLR-4)-expressing monocytes and lymphocyte subpopulations in response to continuous intensive exercise training in athletes, as well as the effect of coenzyme Q10 (CoQ10) supplementation on these changes. Eighteen male elite kendo athletes in Japan were randomly assigned to a CoQ10-supplementation group (n = 9) or a placebo-supplementation group (n = 9) using a double-blind method. Subjects in the CoQ10 group took 300 mg CoQ10 per day for 20 days. Subjects in the placebo group took the same dosage of placebo. All subjects practiced kendo 5.5 h per day for 6 consecutive days during the study period. Blood samples were collected 2 weeks before training, on the first day (day 1), third day (day 3), and fifth day of training (day 5), and 1 week after the training period (post-training) to ascertain TLR-4(+)/CD14(+) monocyte and lymphocyte subpopulations (CD3(+), CD4(+), CD8(+), CD28(+)/CD4(+), CD28(+)/CD8(+), and CD56(+)/CD3(-) cells) using flow cytometry analysis. The group × time interaction for TLR-4(+)/CD14(+) cells did not reach significance (p = 0.08). Within the CoQ10 group, the absolute number of TLR-4(+)/CD14(+) cells was significantly higher only at day 5. The placebo group showed a significant increase in the absolute number of TLR-4(+)/CD14(+) cells at day 3, day 5, and post-training (p < 0.05). There was no significant group × time interaction for any lymphocyte subpopulation. CD3(+), CD8(+), and CD56(+)/CD3(-) cells were significantly reduced at day 3 in both groups (p < 0.05). In conclusion, CoQ10 supplementation might downregulate the increase of TLR-4-expressing monocytes in response to continuous strenuous exercise training in kendo athletes.

    Topics: Adipose Tissue; Athletes; Body Composition; Body Mass Index; Chronic Disease; Dietary Supplements; Double-Blind Method; Down-Regulation; Fatigue; Humans; Inflammation; Lymphocyte Subsets; Male; Martial Arts; Monocytes; Physical Endurance; Sports Nutritional Physiological Phenomena; Toll-Like Receptor 4; Ubiquinone; Young Adult

2015
A randomized controlled trial of coenzyme Q10 for fatigue in the late-onset sequelae of poliomyelitis.
    Complementary therapies in medicine, 2015, Volume: 23, Issue:6

    To determine if coenzyme Q(10) alleviates fatigue in the late-onset sequelae of poliomyelitis.. Parallel-group, randomized, placebo-controlled trial.. Coenzyme Q(10) has been shown to boost muscle energy metabolism in post-polio subjects but it does not promote muscle strength, endurance or function in polio survivors with post-poliomyelitis syndrome. However, the collective increased energy metabolism might contribute to a reduction in post-polio fatigue.. Polio survivors from the Australian post-polio networks in Queensland and New South Wales who attribute a moderate to high level of fatigue to their diagnosed late-onset sequelae of poliomyelitis. Those with fatigue-associated comorbidities of diabetes, anaemia, hypothyroidism and fibromyalgia were excluded.. Participants were assigned (1:1), with stratification of those who use energy-saving mobility aids, to receive 100 mg coenzyme Q(10) or matching placebo daily for 60 days. Participants and investigators were blinded to group allocation. Fatigue was assessed by the Multidimensional Assessment of Fatigue as the primary outcome and the Fatigue Severity Scale as secondary outcome.. Of 103 participants, 54 were assigned to receive coenzyme Q(10) and 49 to receive the placebo. The difference in the mean score reductions between the two groups was not statistically significant for either fatigue measure. Oral supplementation with coenzyme Q(10) was safe and well-tolerated.. A daily dose of 100 mg coenzyme Q(10) for 60 days does not alleviate the fatigue of the late-onset sequelae of poliomyelitis. The registration number for the clinical trial is ACTRN 12612000552886.

    Topics: Aged; Australia; Fatigue; Female; Humans; Male; Middle Aged; Poliomyelitis; Ubiquinone

2015
A randomized, double-blind, placebo-controlled study of oral coenzyme Q10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer.
    The journal of supportive oncology, 2013, Volume: 11, Issue:1

    Coenzyme Q10 (CoQ10) is a common antioxidant supplement with known cardioprotective effects and potential anticancer benefits.. We performed a randomized, double-blind, placebo-controlled study of oral CoQ10 in female breast cancer patients with the primary objective of determining CoQ10's effects on self-reported fatigue, depression, and quality of life (QOL). Methods Eligible women with newly diagnosed breast cancer and planned adjuvant chemotherapy were randomized to oral supplements of 300 mg CoQ10 or placebo, each combined with 300 IU vitamin E, divided into 3 daily doses. Treatment was continued for 24 weeks. Blood tests, QOL measures, and levels of plasma CoQ10 and vitamin E were obtained at baseline and at 8, 16, and 24 weeks. Mixed-effects models were used to assess treatment differences in outcomes over time.. Between September 2004 and March 2009, 236 women were enrolled. Treatment arms were well balanced with respect to age (range, 28-85 years), pathologic stage (stage 0, 91%; stage 1, 8%; stage II, 1%), ethnicity (white, 87%; black, 11%; Hispanic, 2%), and planned therapy. Baseline CoQ10 levels in the CoQ10 and placebo arms were 0.70 and 0.73 microg/mL, respectively; the 24-week CoQ10 levels were 1.83 and 0.79 microg/mL, respectively. There were no significant differences between the CoQ10 and placebo arms at 24 weeks for scores on the Profile of Mood States-Fatigue questionnaire (least squares means, 7.08 vs 8.24, P = .257), the Functional Assessment of Chronic Illness Therapy-Fatigue tool (37.6 vs 37.6, P = .965), the Functional Assessment of Cancer Therapy-Breast Cancer instrument (111.9 vs 110.4, P = .577), or the Center for Epidemiologic Studies-Depression scale (11.6 vs 12.3, P = .632).. Supplementation with conventional doses of CoQ10 led to sustained increases in plasma CoQ10 levels but did not result in improved self-reported fatigue or QOL after 24 weeks of treatment.

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dietary Supplements; Double-Blind Method; Fatigue; Female; Follow-Up Studies; Humans; Middle Aged; Outcome Assessment, Health Care; Patient Participation; Prognosis; Quality of Life; Self Report; Ubiquinone; Vitamins

2013
Increased oxidative stress and coenzyme Q10 deficiency in juvenile fibromyalgia: amelioration of hypercholesterolemia and fatigue by ubiquinol-10 supplementation.
    Redox report : communications in free radical research, 2013, Volume: 18, Issue:1

    Fibromyalgia (FM) is characterized by generalized pain and chronic fatigue of unknown etiology. To evaluate the role of oxidative stress in this disorder, we measured plasma levels of ubiquinone-10, ubiquinol-10, free cholesterol (FC), cholesterol esters (CE), and free fatty acids (FFA) in patients with juvenile FM (n=10) and in healthy control subjects (n=67). Levels of FC and CE were significantly increased in juvenile FM as compared with controls, suggesting the presence of hypercholesterolemia in this disease. However, plasma level of ubiquinol-10 was significantly decreased and the ratio of ubiquinone-10 to total coenzyme Q10 (%CoQ10) was significantly increased in juvenile FM relative to healthy controls, suggesting that FM is associated with coenzyme Q10 deficiency and increased oxidative stress. Moreover, plasma level of FFA was significantly higher and the content of polyunsaturated fatty acids (PUFA) in total FFA was significantly lower in FM than in controls, suggesting increased tissue oxidative damage in juvenile FM. Interestingly, the content of monoenoic acids, such as oleic and palmitoleic acids, was significantly increased in FM relative to controls, probably to compensate for the loss of PUFA. Next, we examined the effect of ubiquinol-10 supplementation (100 mg/day for 12 weeks) in FM patients. This resulted in an increase in coenzyme Q10 levels and a decrease in %CoQ10. No changes were observed in FFA levels or their composition. However, plasma levels of FC and CE significantly decreased and the ratio of FC to CE also significantly decreased, suggesting that ubiquinol-10 supplementation improved cholesterol metabolism. Ubiquinol-10 supplementation also improved chronic fatigue scores as measured by the Chalder Fatigue Scale.

    Topics: Adolescent; Antioxidants; Ataxia; Case-Control Studies; Child; Cholesterol; Dietary Supplements; Double-Blind Method; Fatigue; Fatty Acids, Monounsaturated; Fatty Acids, Nonesterified; Female; Fibromyalgia; Humans; Hypercholesterolemia; Male; Mitochondrial Diseases; Muscle Weakness; Oleic Acid; Oxidative Stress; Pain Measurement; Ubiquinone

2013
Effects of coenzyme Q10 on arterial stiffness, metabolic parameters, and fatigue in obese subjects: a double-blind randomized controlled study.
    Journal of medicinal food, 2011, Volume: 14, Issue:4

    This study investigated the effects of coenzyme Q(10) supplementation on metabolic parameters, inflammatory markers, arterial stiffness, and fatigue in obese subjects. We performed a randomized, double-blind, placebo-controlled, single-center study on 51 obese subjects with a body mass index (BMI) of ≥25 kg/m(2). Subjects were randomized into either a coenzyme Q(10) (200 mg/day) group (n = 26, BMI = 27.9 ± 2.3 kg/m(2), age = 42.7 ± 11.3 years) or a placebo group (n = 25, BMI = 26.8 ± 2.8 kg/m(2), age = 41.3 ± 11.2 years) for a 12-week study. We collected anthropometric measurements, blood for laboratory testing, brachial-ankle pulse wave velocity (baPWV) as an indicator of arterial stiffness, and responses to a fatigue severity scale (FSS) questionnaire at the initial (0 week) and final (12 weeks) visits. A total of 36 subjects successfully completed the study protocol. Serum coenzyme Q(10) levels increased significantly from 0.65 ± 0.27 μg/mL to 1.20 ± 0.38 μg/mL in the coenzyme Q(10) group (P < .001). Oral administration of coenzyme Q(10) did not significantly affect lipid profiles, oxidative and inflammatory markers [including lipoprotein (a), oxidized low-density lipoprotein level, C-reactive protein, and white blood cell count], or baPWV. The mean FSS score decreased significantly from 40.1 to 33.1 in the coenzyme Q(10) group (P = .017), but no significant change was seen in the placebo group (P = .464). However, the extents of the change in mean FSS score between the placebo and coenzyme Q(10) groups were not significantly different (P = .287). In conclusion, we found no evidence that coenzyme Q(10) affects fatigue index, arterial stiffness, metabolic parameters, or inflammatory markers.

    Topics: Administration, Oral; Adult; Ankle Brachial Index; Arteries; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Fatigue; Female; Humans; Male; Middle Aged; Obesity; Surveys and Questionnaires; Ubiquinone; Vascular Resistance

2011
Statins, lack of energy and ubiquinone.
    British journal of clinical pharmacology, 2005, Volume: 59, Issue:5

    Topics: Aged; Double-Blind Method; Fatigue; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pain; Ubiquinone

2005
Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial.
    Alimentary pharmacology & therapeutics, 2003, Volume: 17, Issue:1

    We have previously reported, in an uncontrolled trial, an improvement in fatigue scores in patients with primary biliary cirrhosis given oral antioxidant supplementation. We now present data from a controlled trial.. Sixty-one patients with primary biliary cirrhosis-associated fatigue were randomized into a double-blind, placebo-controlled, cross-over trial. Participants received 12 weeks each of placebo and antioxidant supplementation (vitamins A, C and E, selenium, methionine and ubiquinone) in random order, separated by a 4-week washout period. The primary trial outcome (fatigue) was assessed using the Fisk scale. Other symptoms of primary biliary cirrhosis were measured using Likert and visual analogue scales.. Forty-four patients completed both arms of the trial. No significant changes in fatigue were recorded in the active phase of treatment (median improvement in Fisk score, 1; P = 0.61). Small improvements in Fisk scores were recorded during placebo therapy (median improvement, 4; P = 0.03). Neither medication was associated with improvement in any other symptoms related to primary biliary cirrhosis. Adverse effects were more common during active therapy and were mild and self-limiting. One patient died from unrelated causes during active treatment.. Although oral antioxidant supplementation appears to be safe, we could not find any evidence for a beneficial effect on fatigue or other liver-related symptoms.

    Topics: Administration, Oral; Antioxidants; Ascorbic Acid; Cross-Over Studies; Dietary Supplements; Double-Blind Method; Fatigue; Humans; Liver Cirrhosis, Biliary; Methionine; Selenium; Ubiquinone; Vitamin A; Vitamin E

2003
Case report: oral antioxidant therapy for the treatment of primary biliary cirrhosis: a pilot study.
    Journal of gastroenterology and hepatology, 1999, Volume: 14, Issue:10

    The symptoms of the chronic cholestatic liver disease primary biliary cirrhosis (PBC), in particular fatigue and chronic pruritus, adversely affect quality of life and respond only poorly to treatment. Recent studies have suggested that oxidative stress may play a role in tissue damage in cholestatic liver disease and may contribute to symptoms, such as fatigue. We have, therefore, examined, in an open-label pilot study, the therapeutic effects of antioxidant medication on the biochemistry and symptomatology of PBC.. Patients were randomized to 3 months treatment with a compound antioxidant vitamin preparation (Bio-Antox), four tablets daily (n = 11, group 1), or the combination of Bio-Quinone Q10 (100 mg) with Bio-Antox (n = 13, group 2). Biochemical and symptomatic responses were assessed at 3 months.. Significant improvement in both pruritus and fatigue was seen in the patients in group 2. Mean itch visual analogue score improved from 2.4 +/- 3.0 to 0.4 +/- 0.7 post therapy (P < 0.05) while mean night itch severity score improved from 2.6 +/- 1.9 to 1.3 +/- 0.7 (P < 0.05). Nine of 13 of these patients reported less fatigue, while 10/13 showed an improvement in at least one domain of their Fisk Fatigue Severity Score. No significant improvement in itch and only limited improvement in fatigue were seen in the patients in group 1. No change in biochemical parameters was seen in either group.. Antioxidant therapy, as a combination of Bio-Antox and Bio-Quinone Q10, may improve the pruritus and fatigue of PBC. This combination of therapy should be investigated further in a double-blind, placebo-controlled trial.

    Topics: Antioxidants; Ascorbic Acid; beta Carotene; Coenzymes; Drug Therapy, Combination; Fatigue; Female; Humans; Liver Cirrhosis, Biliary; Male; Methionine; Middle Aged; Pilot Projects; Pruritus; Selenium; Treatment Outcome; Ubiquinone; Vitamin E

1999

Other Studies

9 other study(ies) available for ubiquinone and Fatigue

ArticleYear
Feature of Heart Rate Variability and Metabolic Mechanism in Female College Students with Depression.
    BioMed research international, 2020, Volume: 2020

    To explore the effects of depression on cardiac autonomic nerve function and related metabolic pathways, the heart rate variability (HRV) and urinary differential metabolites were detected on the college students with depression.. 12 female freshmen with depression were filtered by the Beck Depression Inventory (BDI-II) and Self-rating Depression Scale (SDS). By wearing an HRV monitoring system, time domain indexes and frequency domain indexes were measured over 24 hours. Liquid chromatography-mass spectrometry (LC-MS) was used to detect their urinary differential metabolites. Differential metabolites were identified by principal component analysis (PCA) and orthogonal projections to latent structures discriminant analysis (OPLS-DA). The metabolic pathways related to these differential metabolites were analyzed by the MetPA database.. Stress time was significantly increased, and recovery time was markedly decreased in the depression group compared with the control group (. Some autonomic nervous system disruption, high stress, and poor fatigue recovery were confirmed in college students with depression. The metabolic mechanism involved the disruption of coenzyme Q biosynthesis, glycine-serine-threonine metabolism, tyrosine metabolism, pyrimidine metabolism, and steroid metabolism under daily stress.

    Topics: Adolescent; Autonomic Nervous System; Depression; Fatigue; Female; Glycine; Heart Rate; Humans; Metabolomics; Monitoring, Physiologic; Pyrimidines; Serine; Steroids; Stress, Physiological; Students; Threonine; Tyrosine; Ubiquinone; Urine; Young Adult

2020
Ubiquinol-10 Intake Is Effective in Relieving Mild Fatigue in Healthy Individuals.
    Nutrients, 2020, Jun-02, Volume: 12, Issue:6

    Topics: Adult; Dietary Supplements; Double-Blind Method; Fatigue; Female; Healthy Volunteers; Humans; Male; Middle Aged; Motivation; Nutritional Physiological Phenomena; Oxidative Stress; Relaxation; Surveys and Questionnaires; Ubiquinone

2020
Relevance of Mitochondrial Dysfunction in the Reserpine-Induced Experimental Fibromyalgia Model.
    Molecular neurobiology, 2020, Volume: 57, Issue:10

    Fibromyalgia (FM) is one of the most common musculoskeletal pain conditions. Although the aetiology of FM is still unknown, mitochondrial dysfunction and the overproduction of reactive oxygen intermediates (ROI) are common characteristics in its pathogenesis. The reserpine experimental model can induce FM-related symptoms in rodents by depleting biogenic amines. However, it is unclear whether reserpine causes other pathophysiologic characteristics of FM. So far, no one has investigated the relevance of mitochondrial dysfunction in the reserpine-induced experimental FM model using protection- and insult-based mitochondrial modulators. Reserpine (1 mg/kg) was subcutaneously injected once daily for three consecutive days in male Swiss mice. We carried out analyses of reserpine-induced FM-related symptoms, and their modulation by using mitochondrial insult on ATP synthesis (oligomycin; 1 mg/kg, intraperitoneally) or mitochondrial protection (coenzyme Q10; 150 mg/kg/5 days, orally). We also evaluated the effect of reserpine on mitochondrial function using high-resolution respirometry and oxidative status. Reserpine caused nociception, loss in muscle strength, and anxiety- and depressive-like behaviours in mice that were consistent with clinical symptoms of FM, without inducing body weight and temperature alterations or motor impairment. Reserpine-induced FM-related symptoms were increased by oligomycin and reduced by coenzyme Q10 treatment. Reserpine caused mitochondrial dysfunction by negatively modulating the electron transport system and mitochondrial respiration (ATP synthesis) mainly in oxidative muscles and the spinal cord. These results support the role of mitochondria in mediating oxidative stress and FM symptoms in this model. In this way, reserpine-inducing mitochondrial dysfunction and increased production of ROI contribute to the development and maintenance of nociceptive, fatigue, and depressive-like behaviours.

    Topics: Animals; Behavior, Animal; Depression; Disease Models, Animal; Fatigue; Fibromyalgia; Male; Mice; Mitochondria; Models, Biological; Muscles; Nociception; Oxidation-Reduction; Reserpine; Spinal Cord; Ubiquinone

2020
Ubiquinol Supplementation Alters Exercise Induced Fatigue by Increasing Lipid Utilization in Mice.
    Nutrients, 2019, Oct-23, Volume: 11, Issue:11

    Topics: Animal Feed; Animals; Dietary Supplements; Fatigue; Lipid Metabolism; Male; Mice; Mice, Inbred ICR; Muscle Strength; Physical Conditioning, Animal; Specific Pathogen-Free Organisms; Swimming; Ubiquinone

2019
Ubiquinol reduces muscle wasting but not fatigue in tumor-bearing mice.
    Biological research for nursing, 2015, Volume: 17, Issue:3

    Fatigue is the most common and distressing symptom reported by cancer patients during and after treatment. Tumor growth increases oxidative stress and cytokine production, which causes skeletal muscle wasting and cardiac dysfunction. The purpose of this study was to determine whether treatment with the antioxidant ubiquinol improves muscle mass, cardiac function, and behavioral measures of fatigue in tumor-bearing mice.. Adult female mice were inoculated with colon26 tumor cells. Half the control and tumor-bearing mice were administered ubiquinol (500 mg/kg/day) in their drinking water. Voluntary wheel running (i.e., voluntary running activity [VRA]) and grip strength were measured at Days 0, 8, 14, and 17 of tumor growth. Cardiac function was measured using echocardiography on Day 18 or 19. Biomarkers of inflammation, protein degradation, and oxidative stress were measured in serum and heart and gastrocnemius tissue.. VRA and grip strength progressively declined in tumor-bearing mice. Muscle mass and myocardial diastolic function were decreased, and expression of proinflammatory cytokines was increased in serum and muscle and heart tissue on Day 19 of tumor growth. Oxidative stress was present only in the heart, while biomarkers of protein degradation were increased only in the gastrocnemius muscle. Ubiquinol increased muscle mass in the tumor-bearing and control animals but had no effect on the expression of biomarkers of inflammation, protein degradation, or oxidative stress or on behavioral measures of fatigue.

    Topics: Adenocarcinoma; Animals; Antioxidants; Colonic Neoplasms; Fatigue; Female; Mice; Motor Activity; Muscle, Skeletal; Neoplasms, Experimental; Oxidative Stress; Ubiquinone

2015
Antifatigue effect of coenzyme Q10 in mice.
    Journal of medicinal food, 2010, Volume: 13, Issue:1

    The aim of this study was to investigate whether coenzyme Q10 (CoQ10) has an antifatigue effect in mice. ICR male mice were orally given CoQ10 in the form of Bio-Quinone (Pharma Nord, Vejle, Denmark) at doses of 0, 1.5, 15, or 45 mg/kg/day for 4 weeks. Mice were made to perform swimming exercise with loads attached to their tails, corresponding to approximately 5% of their body weights, and the total swimming time until exhaustion was measured. Furthermore, the post-exercise concentration of serum urea nitrogen (SUN), pre-/post-exercise and post-rest concentration of lactic acid (LA), and pre-exercise hepatic glycogen were determined. Mice treated with CoQ10 showed a significantly prolonged exhaustive swim time (15 mg/kg/day; P < .05), increased liver glycogen contents (15 and 45 mg/kg/day; P < .01 and P < .05, respectively), and decreased SUN levels (1.5, 15, and 45 mg/kg/day; P < .01) compared to control animals. The LA level was not significantly changed. These results suggest that CoQ10 improves swimming endurance and has an antifatigue effect.

    Topics: Animals; Blood Urea Nitrogen; Exercise Tolerance; Fatigue; Lactic Acid; Liver; Liver Glycogen; Male; Mice; Mice, Inbred ICR; Muscle Fatigue; Muscle, Skeletal; Physical Conditioning, Animal; Physical Endurance; Swimming; Ubiquinone; Vitamins

2010
Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness.
    Neuro endocrinology letters, 2009, Volume: 30, Issue:4

    There is now evidence that major depression is accompanied by an induction of inflammatory and oxidative and nitrosative stress (IO&NS) pathways and by a lowered antioxidant status. Coenzyme Q10 (CoQ10) is a strong antioxidant that has anti-inflammatory effects.. This paper examines the plasma concentrations of CoQ10 in 35 depressed patients and 22 normal volunteers and the relationships between plasma CoQ10 and treatment resistant depression (TRD), the severity of illness as measured by means of the Hamilton Depression Rating Scale (HDRS) and the presence of chronic fatigue syndrome (CFS).. We found that plasma CoQ10 was significantly (p=0.0002) lower in depressed patients than in normal controls. 51.4% of the depressed patients had plasma CoQ10 values that were lower than the lowest plasma CoQ10 value detected in the controls. Plasma CoQ10 was significantly lower in patients with TRD and with CFS than in the other depressed patients. There were no significant correlations between plasma CoQ10 and the HDRS.. The results show that lower CoQ10 plays a role in the pathophysiology of depression and in particular in TRD and CFS accompanying depression. It is suggested that depressed patients may benefit from CoQ10 supplementation. The findings that lower CoQ10 is a risk factor to coronary artery disease and chronic heart failure (CHF) and mortality due to CHF suggest that low CoQ10 is another factor explaining the risk to cardiovascular disorder in depression. Since statins significantly lower plasma CoQ10, depressed patients and in particular those with TRD and CFS represent populations at risk to statin treatment.

    Topics: Adult; Antidepressive Agents; Biomarkers; Cardiovascular Diseases; Chronic Disease; Depressive Disorder, Major; Drug Resistance; Fatigue; Female; Humans; Male; Middle Aged; Oxidative Stress; Risk Factors; Ubiquinone; Vasculitis

2009
Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation.
    BioFactors (Oxford, England), 2005, Volume: 25, Issue:1-4

    Fifty consecutive new cardiology clinic patients who were on statin drug therapy (for an average of 28 months) on their initial visit were evaluated for possible adverse statin effects (myalgia, fatigue, dyspnea, memory loss, and peripheral neuropathy). All patients discontinued statin therapy due to side effects and began supplemental CoQ(10) at an average of 240 mg/day upon initial visit. Patients have been followed for an average of 22 months with 84% of the patients followed now for more than 12 months. The prevalence of patient symptoms on initial visit and on most recent follow-up demonstrated a decrease in fatigue from 84% to 16%, myalgia from 64% to 6%, dyspnea from 58% to 12%, memory loss from 8% to 4% and peripheral neuropathy from 10% to 2%. There were two deaths from lung cancer and one death from aortic stenosis with no strokes or myocardial infarctions. Measurements of heart function either improved or remained stable in the majority of patients. We conclude that statin-related side effects, including statin cardiomyopathy, are far more common than previously published and are reversible with the combination of statin discontinuation and supplemental CoQ(10). We saw no adverse consequences from statin discontinuation.

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiomyopathies; Coenzymes; Dyspnea; Fatigue; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Memory Disorders; Middle Aged; Muscular Diseases; Pain; Peripheral Nervous System Diseases; Prospective Studies; Ubiquinone

2005
[Clinical aspects of respiratory muscle fatigue].
    Nihon Kyobu Shikkan Gakkai zasshi, 1985, Volume: 23, Issue:9

    Topics: Animals; Coenzymes; Diaphragm; Dogs; Electromyography; Fatigue; Female; Guinea Pigs; Humans; Ubiquinone; Ventilators, Mechanical

1985